Skip to Content

'
Partow Kebriaei, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Partow Kebriaei is an Associate Professor in the Department of Stem Cell Transplant and Cellular Therapy at the MD Anderson Cancer Center in Houston, Texas.  She completed her Hematology and Oncology fellowship training at the University of Chicago, and began her tenure at MD Anderson in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia, as well as autologous and allogeneic stem cell transplantation for lymphoma and leukemia. She is interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy.  More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens.  Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, using umbilical cord blood in combination with a standard allogeneic peripheral blood stem cell transplant to augment the graft versus leukemia effect, and investigating the use of mesenchymal stem cells for the therapy of graft versus host disease.  Dr. Kebriaei has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications.  She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: Unit 423
Houston, TX 77030
Room Number: Faculty Center, FC5.3020

Education & Training

Degree-Granting Education

1997 The University of Texas Health Science Center, Houston, TX, MD, Medicine
1993 Yale University, New Haven, CT, BS, Biology

Postgraduate Training

7/2000-6/2003 Hematology/Oncology Fellowship, Everett Vokes, M.D., University of Chicago Medical Center, Chicago, IL
7/1998-6/2000 Internal Medicine Residency, Daniel W. Foster, M.D., University of Texas Southwestern Medical Center, Dallas, TX
7/1997-6/1998 Internal Medicine Internship, Daniel W. Foster, M.D., University of Texas Southwestern Medical Center, Dallas, TX

Board Certifications

2004 Hematology
2003 Medical Oncology
2001 Internal Medicine

Honors and Awards

2003 Merit Award, American Society of Clinical Oncology
2002 Molecular Biology Workshop, American Association for Cancer Research

Professional Memberships

Committee on Young Clinicians and Investigators (IBMTR), Salt Lake City, UT
Member, 2/2013-2/2014

Selected Publications

Peer-Reviewed Original Research Articles

1. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 6/2011. e-Pub 10/2010. PMID: 20946966.
2. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/2010. PMID: 20674757.
3. Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices 12(5):855-63, 10/2010. PMID: 20574820.
4. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 9/2010. e-Pub 5/2010. PMID: 20466853.
5. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-24, 5/2010. e-Pub 4/2010. PMCID: PMC2873153.
6. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. <i>piggyBac</i> transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. Hum Gene Ther. e-Pub 3/2010. PMID: 19905893.
7. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010. e-Pub 8/2009. PMID: 19668237.
8. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 10/2009. e-Pub 8/2009. PMID: 19654407.
9. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 15(7):804-11, 7/2009. PMID: 19539211.
10. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. Biol Blood Marrow Transplant 15(7):777-84, 7/2009. e-Pub 5/2009. PMCID: PMC2814363.
11. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-6, 1/2009. PMID: 19090005.
12. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res 32(9):1468-71, 9/2008. e-Pub 3/2008. PMID: 18355919.
13. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 49(3):531-7, 3/2008. PMID: 18297531.
14. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2/2008. e-Pub 11/2007. PMID: 17989720.
15. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M. Long-term follow-up of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia. Blood 110(9):3456-62, 11/2007. e-Pub 7/2007. PMID: 17652620.
16. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213-216, 7/2007. PMID: 17593028.
17. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2):340-344, 7/2007. PMID: 17559140.
18. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-462, 4/2007. e-Pub 2/2007. PMID: 17382251.
19. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38(3):203-9, 8/2006. e-Pub 6/2006. PMID: 16799614.
20. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 35(10):965-70, 5/2005. PMID: 15806131.
21. Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res 28(5):537-40, 5/2004. PMID: 15068908.
22. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci U S A 92(19):8813-7, 9/1995. PMCID: PMC41057.
23. Rimm DL, Kebriaei P, Morrow JS. Molecular cloning reveals alternative splice forms of human alpha(E)-catenin. Biochem Biophys Res Commun 203(3):1691-9, 9/1994. PMID: 7945318.

Invited Articles

1. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23(5):1043-63, vi, 10/2009. PMID: 19825452.
2. Ravandi F, Kebriaei P. Cytokines in the treatment of acute leukemias. Cancer Treat Res 126:313-31, 2005. PMID: 16209072.
3. Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 10(4):284-9, 7/2003. PMID: 12799534.
4. Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 15(4):597-621, 12/2002. PMID: 12617866.

Book Chapters

1. Kebriaei P, Ravandi F. Cytokines in the treatment of acute leukemias. in press. In: Cytokines and Cancer. Kluwer Academic Publishers, 2005.
2. Kebriaei P, Champlin R. The role of allogeneic stem cell transplantation in the therapy of adult acute lymphoblastic leukemia (ALL). in press. In: Springer. Springer Publications, 2007.
3. Kebriaei P., Giralt S. The role of autologous stem cell transplantation in the management of acute lymphoblastic leukemia in adults. In: Springer. Springer Publications, 2007.
4. Champlin R, Estey E, Kebriaei P, and de Lima M. Management of Acute Leukemias in Cancer. In: Principles and Practice of Oncology, 8th. Ed(s) De Vita, Hellman, Rosenberg, 2008.
5. Kebriaei P. The Role of Hematopoietic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia. In: Leukemia Principles and Practice of Therapy. Blackwell Publishing. In Press.
6. Kebriaei P, Champlin R, Estey E, de Lima M. Management of Acute Leukemias in Cancer. In: Principles and Practice of Oncology, 9th. De Vita, Hellman, Rosenberg, 2010.

Last updated: 7/16/2013